1   Preface
2   Scope and Methodology
    2.1    Objectives of the Study
    2.2    Stakeholders
    2.3    Data Sources
        2.3.1    Primary Sources
        2.3.2    Secondary Sources
    2.4    Market Estimation
        2.4.1    Bottom-Up Approach
        2.4.2    Top-Down Approach
    2.5    Forecasting Methodology
3   Executive Summary
4   Introduction
    4.1    Overview
    4.2    Key Industry Trends
5   Global Peptide Therapeutics Market
    5.1    Market Overview
    5.2    Market Performance
    5.3    Impact of COVID-19
    5.4    Market Forecast
6   Market Breakup by Type
    6.1    Innovative
        6.1.1 Market Trends
        6.1.2 Market Forecast
    6.2    Generic
        6.2.1 Market Trends
        6.2.2 Market Forecast
7   Market Breakup by Type of Manufacturer
    7.1    Outsourced
        7.1.1 Market Trends
        7.1.2 Market Forecast
    7.2    In-house
        7.2.1 Market Trends
        7.2.2 Market Forecast
8   Market Breakup by Synthesis Technology
    8.1    Solid Phase Peptide Synthesis
        8.1.1 Market Trends
        8.1.2 Market Forecast
    8.2    Liquid Phase Peptide Synthesis
        8.2.1 Market Trends
        8.2.2 Market Forecast
    8.3    Hybrid Technology
        8.3.1 Market Trends
        8.3.2 Market Forecast
9   Market Breakup by Routes of Administration
    9.1    Parenteral
        9.1.1 Market Trends
        9.1.2 Market Forecast
    9.2    Oral
        9.2.1 Market Trends
        9.2.2 Market Forecast
    9.3    Others
        9.3.1 Market Trends
        9.3.2 Market Forecast
10  Market Breakup by Application
    10.1    Gastrointestinal Disorders
        10.1.1 Market Trends
        10.1.2 Market Forecast
    10.2    Neurological Disorders
        10.2.1 Market Trends
        10.2.2 Market Forecast
    10.3    Metabolic Disorders
        10.3.1 Market Trends
        10.3.2 Market Forecast
    10.4    Cancer
        10.4.1 Market Trends
        10.4.2 Market Forecast
    10.5    Others
        10.5.1 Market Trends
        10.5.2 Market Forecast
11  Market Breakup by Region
    11.1    North America
        11.1.1 United States
           11.1.1.1 Market Trends
           11.1.1.2 Market Forecast
        11.1.2 Canada
           11.1.2.1 Market Trends
           11.1.2.2 Market Forecast
    11.2    Asia-Pacific
        11.2.1 China
           11.2.1.1 Market Trends
           11.2.1.2 Market Forecast
        11.2.2 Japan
           11.2.2.1 Market Trends
           11.2.2.2 Market Forecast
        11.2.3 India
           11.2.3.1 Market Trends
           11.2.3.2 Market Forecast
        11.2.4 South Korea
           11.2.4.1 Market Trends
           11.2.4.2 Market Forecast
        11.2.5 Australia
           11.2.5.1 Market Trends
           11.2.5.2 Market Forecast
        11.2.6 Indonesia
           11.2.6.1 Market Trends
           11.2.6.2 Market Forecast
        11.2.7 Others
           11.2.7.1 Market Trends
           11.2.7.2 Market Forecast
    11.3    Europe
        11.3.1 Germany
           11.3.1.1 Market Trends
           11.3.1.2 Market Forecast
        11.3.2 France
           11.3.2.1 Market Trends
           11.3.2.2 Market Forecast
        11.3.3 United Kingdom
           11.3.3.1 Market Trends
           11.3.3.2 Market Forecast
        11.3.4 Italy
           11.3.4.1 Market Trends
           11.3.4.2 Market Forecast
        11.3.5 Spain
           11.3.5.1 Market Trends
           11.3.5.2 Market Forecast
        11.3.6 Russia
           11.3.6.1 Market Trends
           11.3.6.2 Market Forecast
        11.3.7 Others
           11.3.7.1 Market Trends
           11.3.7.2 Market Forecast
    11.4    Latin America
        11.4.1 Brazil
           11.4.1.1 Market Trends
           11.4.1.2 Market Forecast
        11.4.2 Mexico
           11.4.2.1 Market Trends
           11.4.2.2 Market Forecast
        11.4.3 Others
           11.4.3.1 Market Trends
           11.4.3.2 Market Forecast
    11.5    Middle East and Africa
        11.5.1 Market Trends
        11.5.2 Market Breakup by Country
        11.5.3 Market Forecast
12  SWOT Analysis
    12.1    Overview
    12.2    Strengths
    12.3    Weaknesses
    12.4    Opportunities
    12.5    Threats
13  Value Chain Analysis
14  Porters Five Forces Analysis
    14.1    Overview
    14.2    Bargaining Power of Buyers
    14.3    Bargaining Power of Suppliers
    14.4    Degree of Competition
    14.5    Threat of New Entrants
    14.6    Threat of Substitutes
15  Price Analysis
16  Competitive Landscape
    16.1    Market Structure
    16.2    Key Players
    16.3    Profiles of Key Players
        16.3.1    Amgen Inc.
           16.3.1.1 Company Overview
           16.3.1.2 Product Portfolio
           16.3.1.3 Financials
           16.3.1.4 SWOT Analysis
        16.3.2    Apitope International NV
           16.3.2.1 Company Overview
           16.3.2.2 Product Portfolio
        16.3.3    Arch Biopartners Inc.
           16.3.3.1 Company Overview
           16.3.3.2 Product Portfolio
           16.3.3.3 Financials
        16.3.4    AstraZeneca plc
           16.3.4.1 Company Overview
           16.3.4.2 Product Portfolio
           16.3.4.3 Financials
           16.3.4.4 SWOT Analysis
        16.3.5    Circle Pharma Inc.
           16.3.5.1 Company Overview
           16.3.5.2 Product Portfolio
        16.3.6    Corden Pharma GmbH
           16.3.6.1 Company Overview
           16.3.6.2 Product Portfolio
        16.3.7    F. Hoffmann-La Roche AG
           16.3.7.1 Company Overview
           16.3.7.2 Product Portfolio
           16.3.7.3 SWOT Analysis
        16.3.8    Ipsen Group
           16.3.8.1 Company Overview
           16.3.8.2 Product Portfolio
           16.3.8.3 Financials
           16.3.8.4 SWOT Analysis
        16.3.9    Lonza Group AG
           16.3.9.1 Company Overview
           16.3.9.2 Product Portfolio
           16.3.9.3 Financials
           16.3.9.4 SWOT Analysis
        16.3.10    Novo Nordisk A/S
           16.3.10.1 Company Overview
           16.3.10.2 Product Portfolio
           16.3.10.3 Financials
           16.3.10.4 SWOT Analysis
        16.3.11    Pfizer Inc.
           16.3.11.1 Company Overview
           16.3.11.2 Product Portfolio
           16.3.11.3 Financials
           16.3.11.4 SWOT Analysis
        16.3.12    Teva Pharmaceuticals Industries Ltd.
           16.3.12.1 Company Overview
           16.3.12.2 Product Portfolio
           16.3.12.3 Financials
           16.3.12.4 SWOT Analysis
        16.3.13    Zealand Pharma A/S
           16.3.13.1 Company Overview
           16.3.13.2 Product Portfolio
           16.3.13.3 Financials
❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer



 
			 
					
							
			 
					
							
			 
					
							
			 
					
							
			 
					
							
			 
					
							
			 
					
							
			 
					
							
			